Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team..

Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382.

PMID:
18444831
2.

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.

Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH, Cox C, Nelsen AJ, Hughes S, Thorborn DE, Stancil B, Hetherington SV, Burns DK, Roses AD.

Pharmacogenomics J. 2008 Dec;8(6):365-74. doi: 10.1038/tpj.2008.3. Epub 2008 Mar 11. Review.

PMID:
18332899
3.

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.

Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B.

Sci China Life Sci. 2013 Feb;56(2):119-24. doi: 10.1007/s11427-013-4438-8. Epub 2013 Feb 8. Review. Erratum in: Sci China Life Sci. 2013 Mar;56(3):292.

PMID:
23393027
4.

Abacavir hypersensitivity reaction: an update.

Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE.

Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26. Review.

PMID:
18303141
5.

Successful translation of pharmacogenetics into the clinic: the abacavir example.

Phillips E, Mallal S.

Mol Diagn Ther. 2009;13(1):1-9. doi: 10.2165/01250444-200913010-00001. Review.

PMID:
19351209
6.

Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis.

Tangamornsuksan W, Lohitnavy O, Kongkaew C, Chaiyakunapruk N, Reisfeld B, Scholfield NC, Lohitnavy M.

J Pharm Pharm Sci. 2015;18(1):68-76. Review.

7.

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.

Hughes AR, Brothers CH, Mosteller M, Spreen WR, Burns DK.

Pharmacogenomics. 2009 Feb;10(2):225-33. doi: 10.2217/14622416.10.2.225. Review.

PMID:
19207023
8.

Abacavir pharmacogenetics--from initial reports to standard of care.

Martin MA, Kroetz DL.

Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3. Review.

9.

HLA alleles and drug hypersensitivity reactions.

Profaizer T, Eckels D.

Int J Immunogenet. 2012 Apr;39(2):99-105. doi: 10.1111/j.1744-313X.2011.01061.x. Epub 2011 Dec 3. Review.

PMID:
22136512
10.

Human leukocyte antigens and drug hypersensitivity.

Chung WH, Hung SI, Chen YT.

Curr Opin Allergy Clin Immunol. 2007 Aug;7(4):317-23. Review.

PMID:
17620823
11.

Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.

Lai-Goldman M, Faruki H.

Genet Med. 2008 Dec;10(12):874-8. doi: 10.1097/GIM.0b013e31818de71c. Review.

PMID:
19092439
12.

Pharmacogenetic information derived from analysis of HLA alleles.

Gatanaga H, Honda H, Oka S.

Pharmacogenomics. 2008 Feb;9(2):207-14. doi: 10.2217/14622416.9.2.207. Review.

PMID:
18370849
13.

Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01.

Sousa-Pinto B, Pinto-Ramos J, Correia C, Gon├žalves-Costa G, Gomes L, Gil-Mata S, Ara├║jo L, Delgado L.

J Allergy Clin Immunol. 2015 Oct;136(4):1092-4.e3. doi: 10.1016/j.jaci.2015.03.019. Epub 2015 Apr 29. Review. No abstract available.

PMID:
25934581
14.

The abacavir hypersensitivity reaction: a review.

Clay PG.

Clin Ther. 2002 Oct;24(10):1502-14. Review.

PMID:
12462283
15.

HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.

Nolan D.

Crit Rev Clin Lab Sci. 2009;46(3):153-65. doi: 10.1080/10408360902937817. Review.

PMID:
19514905
16.

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

Roses AD.

Neuropsychopharmacology. 2009 Jan;34(1):6-17. doi: 10.1038/npp.2008.153. Epub 2008 Oct 15. Review.

17.

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL; Clinical Pharmacogenetics Implementation Consortium..

Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29. Review.

18.

Pharmacogenetics of drug hypersensitivity.

Phillips EJ, Mallal SA.

Pharmacogenomics. 2010 Jul;11(7):973-87. doi: 10.2217/pgs.10.77. Review.

19.

Evaluation and management of hypersensitivity to proton pump inhibitors.

Bose S, Guyer A, Long A, Banerji A.

Ann Allergy Asthma Immunol. 2013 Dec;111(6):452-7. doi: 10.1016/j.anai.2013.08.022. Epub 2013 Sep 18. Review.

PMID:
24267357
20.

Human leukocyte antigen-associated drug hypersensitivity.

Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J.

Curr Opin Immunol. 2013 Feb;25(1):81-9. doi: 10.1016/j.coi.2012.10.002. Epub 2012 Nov 8. Review.

PMID:
23141566

Supplemental Content

Support Center